Mason, Ohio — According to state and local development sources, AtriCure plans to invest $45,000,000.00 to build out 120,000 square feet of new space in Mason. The company is creating 400 new jobs at this facility. The company plans to occupy the new space at 7555 Innovation Way in Mason, on or about April 1, 2026. According to the company website AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCures Isolator Synergy Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCures AtriClip Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCures Hybrid AF Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCures cryoICE cryoSPHERE probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.

To learn more about AtriCure, visit http://www.atricure.com/

Company Contact:
Michael Carrel, Chief Executive Officer
https://www.linkedin.com/in/michael-carrel-2493511/
513-755-4100

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.